Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation
Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation
PALO ALTO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has paid off the remaining balance of approx. $1,300,000 under the convertible debentures (the "Convertible Debentures") previously issued and sold to YA II PN, Ltd. ("Yorkville") in March 2023.
加利福尼亞州帕洛阿爾託，2024年3月19日（GLOBE NEWSWIRE）——專注於收購、開發和商業化用於治療急慢性疼痛的非阿片類疼痛管理產品的創新創收公司Scilex控股公司（納斯達克股票代碼：SCLX，“Scilex”）今天宣佈，它已償還了可轉換債券（“可轉換債券”）下約13萬美元的剩餘餘額債券”）此前曾於2023年3月發行並出售給YA II PN, Ltd.（“約克維爾”）。
Scilex has also voluntarily made an early payment in the aggregate amount of $15,000,000 under the senior secured promissory note (the "Oramed Note") issued to Oramed Pharmaceuticals Inc. (Nasdaq: ORMP, "Oramed") in September 2023.
Scilex還根據2023年9月向奧拉美製藥公司（納斯達克股票代碼：ORMP，“Oramed”）發行的優先有擔保本票（“Oramed票據”）自願提前支付了總額爲1500萬美元的款項。
"This is a pivotal moment for Scilex, signaling our readiness to embrace new opportunities and transform the lives of patients with acute and chronic pain while addressing the opioid crisis. With a stronger balance sheet, we are well-positioned to pursue collaborations, expand our current commercialization efforts, and bring additional innovative opioid sparing treatments to market," said Jaisim Shah, Chief Executive Officer and President of Scilex.
“對於Scilex來說，這是一個關鍵時刻，這表明我們願意在應對阿片類藥物危機的同時，抓住新機遇，改變急慢性疼痛患者的生活。Scilex首席執行官兼總裁Jaisim Shah表示，憑藉更強的資產負債表，我們完全有能力開展合作，擴大我們目前的商業化工作，並將更多創新的阿片類藥物節約療法推向市場。